{"id":502092,"date":"2020-08-13T14:04:01","date_gmt":"2020-08-13T14:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=502092"},"modified":"2020-08-13T14:04:01","modified_gmt":"2020-08-13T14:04:01","slug":"cutaneous-lupus-erythematosus-emerging-drugs-and-key-players-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-lupus-erythematosus-emerging-drugs-and-key-players-delveinsight_502092.html","title":{"rendered":"Cutaneous Lupus Erythematosus Emerging drugs and Key Players | DelveInsight"},"content":{"rendered":"
\"Cutaneous<\/a><\/p>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
“Cutaneous Lupus Erythematosus (CLE) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cutaneous Lupus Erythematosus (CLE) market. A detailed picture of the Cutaneous Lupus Erythematosus (CLE) pipeline landscape is provided, which includes the disease overview and Cutaneous Lupus Erythematosus (CLE) treatment guidelines.<\/div>\n

Cutaneous Lupus Erythematosus is a chronic, autoimmune disease affecting the skin, which belongs to the family of lupus erythematosus where the symptoms are restricted to the skin.<\/p>\n

The available therapeutics options in Cutaneous Lupus Erythematosus treatment Landscape<\/strong> <\/a>aim to reduce complications arising from Lupus Erythematosus.<\/p>\n

Cutaneous Lupus Erythematosus Emerging Drugs<\/strong><\/a><\/p>\n

    \n
  1. BIIB059: Biogen<\/li>\n
  2. Etanercept: Pfizer<\/li>\n
  3. Filgotinib: Galapagos NV \/Gilead Sciences<\/li>\n
  4. GS-9876: Gilead Sciences<\/li>\n
  5. Delgocitinib: LEO Pharma\/ Japan Tobacco<\/li>\n
  6. VIB7734: VIELABIO<\/li>\n<\/ol>\n

     <\/p>\n

    BIIB059 (Biogen) is an investigational, humanized monoclonal antibody that acts as a BDCA2 inhibitor. BDCA2 is uniquely expressed on the surface of human pDCs (plasmacytoid dendritic cells) that synthesize large amounts of interferon. BIIB059 binding to BDCA2 results in its rapid internalization from the cell surface of human pDCs and the subsequent inhibition of IFN-I (all subtypes), cytokine, and chemokine production by pDCs. Biogen is conducting a Phase II clinical trial for the treatment of active Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus.<\/p>\n

    Etanercept is a dimeric, soluble form of a fully human tumor necrosis factor (TNF) receptor that can bind TNF molecules and inhibits binding of TNF-α and TNF-β to cell surface TNFRs, rendering TNF are biologically inactive. Its clinical efficacy and safety profile are established as disease-modifying agent for arthritis. The systemic administration of TNF blockers has been associated with the induction of pathogenic autoantibodies that may render SLE worse or progression from DLE only to SLE. Administering a TNF blocker, Etanercept using the intra-dermal route will provide local concentration to neutralize TNF in tissue while minimizes the effect to systemic immunity. Currently, Pfizer has completed Phase II clinical trial for the treatment of Discoid Lupus Erythematosus.<\/p>\n

    Along with the above-proven candidates, various other potential therapies are also being developed by big pharmaceutical companies for this rare indication, such as Filgotinib (Galapagos NV \/Gilead Sciences), VIB7734 (Viela Bio), Delgocitinib (LEO Pharma), GS-9876 (Gilead Sciences), Secukinumab (Novartis), Tofacitinib (Pfizer) and others.<\/p>\n

    Overall, the increasing research in this condition along with upcoming novel therapies will fuel the market during the forecast period, 2020-2030.<\/p>\n

     <\/p>\n

    Scope of the report<\/strong><\/p>\n